Atossa Therapeutics (ATOS) Stock: Buy, Sell, or Hold?
ATOS - Atossa Therapeutics, Inc. Common Stock
$2.34
0.07 (3.08%)
▲
5d:
+23.16%
30d:
-4.88%
90d:
+2.63%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When ATOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ATOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ATOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ATOS is currently trading at $2.34, which is considered fair relative to its 30-day fair value range of $2.13 to $2.57.
Technical Outlook: Technically, ATOS is in a strong downtrend. Immediate support is located at $1.82, while resistance sits at $2.43. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ATOS scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.00 (+712.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ATOS is in a strong downtrend. Immediate support is located at $1.82, while resistance sits at $2.43. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ATOS scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.00 (+712.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.13 -
$2.57
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (76/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 712.0% below Wall St target ($19.00)
- CAUTION: Bottoming setup, but lagging the sector by 22% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.13 -
$2.57
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.82
Resistance Level
$2.43
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.71
Wall Street Target
$19.00
(+712.0%)
Share & Embed Analysis
Last updated: October 03, 2026 3:54 PM ET
Data refreshes hourly during market hours. Next update: 4:54 PM
Data refreshes hourly during market hours. Next update: 4:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
